ClinicalTrials.gg
CompletedNCT02394340Updated Nov 27, 2019Results posted

Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Participants With Tinea Pedis and Tinea Cruris

A Phase 4 interventional study of Omeprazole 40 mg and Luliconazole Cream 1% in Tinea Pedis and Tinea Cruris, sponsored by Bausch & Lomb Incorporated. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-27.

Sponsored by Bausch & Lomb Incorporated (part of Bausch Health Companies Inc.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies in Tinea Pedis with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Tinea Pedis · United States.

Enrollment
29th of 29
20 · median 160
Started
2015
with 1 other
Phase 4
2 of 30
none open now
Registered
20th of 30
by date
Lead sponsor
1 of 30
Bausch & Lomb Incorporated

Among the 30 studies in Tinea Pedis with a site in United States, this one is the 29th largest by enrollment of the 29 interventional ones that give a count, is one of 2 that started in 2015, is one of 2 in phase 4, and was the 20th registered.

Tinea Pedis

73 studies on the registry are indexed under Tinea Pedis; 8 are open to participants now.

Browse Tinea Pedis studies →

Open to participants now

1 of the 30 studies in Tinea Pedis with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Tinea Pedis studies recruiting now, 2 set no upper age limit and 3 stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Tinea Pedis with a site in United States, or all of them as a file.
02

Study summary

This is an open-label, maximal use study to evaluate whether luliconazole in plasma acts as an inhibitor of cytochrome P2C19 (CYP2C19) as measured by circulating levels of omeprazole before and after treatment with a maximum dose of luliconazole cream 1% in participants with moderate to severe tinea pedis and tinea cruris.

03

Conditions studied

  • Tinea Pedis
  • Tinea Cruris

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with a clinical diagnosis of moderate to severe interdigital tinea pedis, as defined by a Physician's Global Assessment (PGA) score of 2 or 3 on both feet, and moderate to severe tinea cruris, as defined by a PGA score of 2 or 3
  • Participants with a mycological diagnosis of tinea pedis and tinea cruris confirmed by the detection of fungal hyphae on a microscopic potassium hydroxide (KOH) wet mount
  • Participants must be in good general health and free of any disease that might interfere with study evaluations
  • Participants with the ability and willingness to follow all study procedures, attend all scheduled visits, and successfully complete the study

Exclusion criteria

Exclusion Criteria:

  • Female participants who are pregnant and/or nursing or planning a pregnancy during the course of the trial
  • Participants who are
  • Participants who have a recent history of or currently known drug or alcohol abuse
  • Participants with a history of intolerance or to imidazole compounds, proton pump inhibitors, or the inactive components of luliconazole cream 1% or omeprazole
  • Participants with a life-threatening condition within the last 6 months
  • Participants with uncontrolled diabetes mellitus
  • Participants who are unable to communicate or cooperate with the Investigator
  • Participants using medications for treatment of tinea pedis and/or tinea cruris (see Investigator for length of time prior to study start)
  • Participants receiving concomitant drugs that are known to inhibit and/or induce CYP2C19 and/or , or that interact with omeprazole
  • Because of the potential for drug interaction with luliconazole, administration with medications that are known to be substrates of CYP3A4, CYP2B6, CYP2C8, and CYP2C19 should be carefully monitored
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Luliconazole Cream 1%

    Participants will receive 1 oral capsule of omeprazole 40 milligrams (mg) on Day 1 and Day 8. Participants will also receive luliconazole cream 1% to cover the entire affected surface areas and adjacent areas once daily in the morning on Day 2 (24 hours after initial omeprazole dosing) through Day 8.

    Drug: Omeprazole 40 mg · Drug: Luliconazole Cream 1%

Interventions

  • DrugOmeprazole 40 mg

    Oral capsule to be taken as per the instructions regarding proper dosing technique.

  • Topical cream to be applied as per the instructions regarding proper study drug application technique.

    Also known as: LUZU Cream 1%

06

What researchers measure

Primary outcomes

  1. Circulating Levels (Plasma Concentration) of Omeprazole Prior to Treatment With Luliconazole Cream 1%

    Circulating plasma levels of omeprazole were measured using validated liquid chromatography with tandem mass spectrometry detection (LS/MS-MS) methods. The range for omeprazole determination was 4.64-9.27 nanograms/milliliter (ng/mL). Serial blood sampling occurred in each enrolled participant up to 24 hours post treatment (Day 1) with omeprazole (before the start of luliconazole cream 1% treatment on Day 2).

    Time frame: 15 minutes predose; 15, 30, 45, and 60 minutes postdose; and 1.5, 2, 2.5, 3, 4, 6, 8, 10, and 24 hours postdose of omeprazole on Day 1

  2. Circulating Levels (Plasma Concentration) of Omeprazole After 1 Week of Treatment With Luliconazole Cream 1%

    Circulating plasma levels of omeprazole were measured using validated LS/MS-MS methods. The range for omeprazole determination was 4.64-9.27 ng/mL. Serial blood sampling occurred in each enrolled participant up to 24 hours post treatment (Day 8) with omeprazole (after using luliconazole cream 1% treatment for 1 week).

    Time frame: 15 minutes predose; 15, 30, 45, and 60 minutes postdose; and 1.5, 2, 2.5, 3, 4, 6, 8, 10, and 24 hours postdose of omeprazole on Day 8

07

Results

Posted Nov 27, 2019
Limitations and caveats
This study was designed to test a maximal use of luliconazole cream 1% to evaluate the highest systemic exposure of luliconazole, but the doses administered were higher than intended by approximately 25%.

Participant flow

Participant flow — Overall Study
MilestoneLuliconazole Cream 1%
Started20
Received at least 1 dose of study drug20
Completed18
Not completed2
Withdrew: Failed drug screen test1
Withdrew: Adverse event1

Outcome measures

PrimaryCirculating Levels (Plasma Concentration) of Omeprazole Prior to Treatment With Luliconazole Cream 1%

Circulating plasma levels of omeprazole were measured using validated liquid chromatography with tandem mass spectrometry detection (LS/MS-MS) methods. The range for omeprazole determination was 4.64-9.27 nanograms/milliliter (ng/mL). Serial blood sampling occurred in each enrolled participant up to 24 hours post treatment (Day 1) with omeprazole (before the start of luliconazole cream 1% treatment on Day 2).

Time frame:
15 minutes predose; 15, 30, 45, and 60 minutes postdose; and 1.5, 2, 2.5, 3, 4, 6, 8, 10, and 24 hours postdose of omeprazole on Day 1
Reported as:
Mean · ng/mL
Circulating Levels (Plasma Concentration) of Omeprazole Prior to Treatment With Luliconazole Cream 1%
ng/mLLuliconazole Cream 1%
Predose0 ± 0
15 minutes postdose0 ± 0
30 minutes postdose23.67 ± 89.46
45 minutes postdose196.30 ± 301.31
1 hour postdose463.74 ± 546.51
1.5 hours postdose526.98 ± 499.60
2 hours postdose655.70 ± 520.31
2.5 hours postdose621.08 ± 464.55
3 hours postdose636.60 ± 508.53
4 hours postdose468.79 ± 355.49
6 hours postdose235.20 ± 214.29
8 hours postdose129.70 ± 129.08
10 hours postdose74.24 ± 84.54
24 hours postdose3.32 ± 6.18
PrimaryCirculating Levels (Plasma Concentration) of Omeprazole After 1 Week of Treatment With Luliconazole Cream 1%

Circulating plasma levels of omeprazole were measured using validated LS/MS-MS methods. The range for omeprazole determination was 4.64-9.27 ng/mL. Serial blood sampling occurred in each enrolled participant up to 24 hours post treatment (Day 8) with omeprazole (after using luliconazole cream 1% treatment for 1 week).

Time frame:
15 minutes predose; 15, 30, 45, and 60 minutes postdose; and 1.5, 2, 2.5, 3, 4, 6, 8, 10, and 24 hours postdose of omeprazole on Day 8
Reported as:
Mean · ng/mL
Circulating Levels (Plasma Concentration) of Omeprazole After 1 Week of Treatment With Luliconazole Cream 1%
ng/mLLuliconazole Cream 1%
Predose0 ± 0
15 minutes postdose0 ± 0
30 minutes postdose18.11 ± 68.24
45 minutes postdose142.72 ± 298.29
1 hour postdose317.21 ± 401.97
1.5 hours postdose637.56 ± 509.09
2 hours postdose763.51 ± 607.80
2.5 hours postdose700.91 ± 423.74
3 hours postdose730.56 ± 349.10
4 hours postdose586.83 ± 309.83
6 hours postdose323.40 ± 219.50
8 hours postdose190.15 ± 154.82
10 hours postdose111.51 ± 102.30
24 hours postdose6.84 ± 10.01

Adverse events

Collected over Baseline up to Day 9. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Luliconazole Cream 1%—0/20 (0%)4/20 (20%)
Most frequent other events
Most frequent other events
EventLuliconazole Cream 1%
Muscle strainInjury, poisoning and procedural complications1/20
Alanine aminotransferase increasedInvestigations1/20
Aspartate Aminotransferase increasedInvestigations1/20
Hemoglobin decreasedInvestigations1/20
Back painMusculoskeletal and connective tissue disorders1/20

Baseline characteristics

All participants who received at least 1 application of study drug and had at least 1 post-Baseline assessment.

Age, Continuous
Age, Continuous(years)Luliconazole Cream 1%
Mean45.05 ± 10.47
Sex: Female, Male
Sex: Female, Male(Participants)Luliconazole Cream 1%
Female1
Male19
08

Study locations

1 site
  • TKL Research
    Fair Lawn, New Jersey 07410, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2015 to primary completion in Apr 2015, 1 month.

Results were first posted in Nov 2019, 4 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2015
First posted
Mar 20, 2015
StartActual
Feb 3, 2015
Primary completionActual
Apr 1, 2015
CompletionActual
Apr 1, 2015
Results first posted
Nov 27, 2019
Last update
Nov 27, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02394340
Responsible party
Sponsor
First posted
Mar 20, 2015
Start date
Feb 3, 2015
Primary completion
Apr 1, 2015
Completion
Apr 1, 2015
Results posted
Nov 27, 2019
Last update
Nov 27, 2019

Study contacts

Anya Loncaric
study director · Bausch Health Americas, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Luliconazole

Start the discussion